Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome

Breast Cancer Research and Treatment

Volumn 148, Issue 1, 2014, Pages 211-220

  Baglia, Michelle L ^a   Cai, Qiuyin ^a   Zheng, Ying ^b   Wu, Jie ^a   Su, Yinghao ^a   Ye, Fei ^a   Bao, Ping Ping ^b   Cai, Hui ^a   Zhao, Zhiguo ^a   Balko, Justin ^a   Zheng, Wei ^a   Lu, Wei ^b   Shu, Xiao Ou ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cohort study; DUSP4; Mortality; Recurrence; Triple negative breast cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DUAL SPECIFICITY PHOSPHATASE 4 GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MKI67 GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TP53 GENE; TRIPLE NEGATIVE BREAST CANCER; YOUNG ADULT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

DUAL SPECIFICITY PHOSPHATASE; DUSP4 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84921938603     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3127-z     Document Type: Article

References (21)

1. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627–636. doi:10.1007/s10549-010-1293-1
2. Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, Vansant G, Monforte J, Daraselia N (2011) Exploring molecular pathways of triple-negative breast cancer. Genes cancer 2(9):870–879. doi:10.1177/1947601911432496
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045
4. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL (2012) Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18(7):1052–1059. doi:10.1038/nm.2795
5. Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discovery 6(5):391–403. doi:10.1038/nrd2289
6. Lawan A, Al-Harthi S, Cadalbert L, McCluskey AG, Shweash M, Grassia G, Grant A, Boyd M, Currie S, Plevin R (2011) Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J Biol Chem 286(15):12933–12943. doi:10.1074/jbc.M110.181370
7. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, Pietsch T (2010) Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res 70(4):1689–1699. doi:10.1158/0008-5472.CAN-09-3218
8. Cagnol S, Rivard N (2013) Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene 32(5):564–576. doi:10.1038/onc.2012.88
9. Rottenberg S, Jonkers J (2012) MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. Breast cancer res 14(6):324. doi:10.1186/bcr3327
10. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W (2009) Soy food intake and breast cancer survival. JAMA 302(22):2437–2443. doi:10.1001/jama.2009.1783
11. Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292. doi:10.1186/1471-2407-11-292
12. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, Dimitrov K (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26(3):317–325. doi:10.1038/nbt1385
13. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. doi:10.1200/JCO.2008.18.1370
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235. doi:10.1007/s10549-006-9242-8
15. Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D’Amico R, Giovannelli S, Maiorana A, Jovic G, Conte P (2009) A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol Off J European Soc Med Oncol 20(7):1193–1198. doi:10.1093/annonc/mdn761
16. Peng DJ, Zhou JY, Wu GS (2010) Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. Cell Cycle 9(23):4650–4655
17. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11–22. doi:10.1038/nrc969
18. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S (2014) Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 34(3):1071–1077
19. Sabatier R, Goncalves A, Bertucci F (2014) Personalized medicine: present and future of breast cancer management. Crit Rev Oncol Hematol 91(3):223–233. doi:10.1016/j.critrevonc.2014.03.002
20. Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL (2011) Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res 13(5):R85. doi:10.1186/bcr2937
21. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967